

Volume 88(1) - 2015

Journal of Biological Research

Bollettino della Società Italiana di Biologia Sperimentale



86th SIBS National Congress

Palermo, Italy, 24-25 October 2013

Botanical Garden, Lanza Hall

www.jbiolres.org

jbr

pagepress

Journal of Biological Research

Bollettino della Società Italiana di Biologia Sperimentale

eISSN 2284-0230

EDITOR IN CHIEF

Marco Giammanco (*University of Palermo, Italy*)

ASSOCIATE EDITORS

Renzo Antolini (*University of Trento, Italy*)

Massimo Cocchi (*Alma Mater Studiorum-University of Bologna, Italy*)

Proto Gavino Pippia (*University of Sassari, Italy*)

Luigi Pane (*University of Genoa, Italy*)

Emma Rabino Massa (*University of Turin, Italy*)

EDITORIAL BOARD

James Anthony (*Michigan State University, USA*)

Maria Grazia Bridelli (*University of Parma, Italy*)

Dario Cantino (*University of Turin, Italy*)

David Caramelli (*University of Florence, Italy*)

Giuseppe Caramia (*G. Salesi Ancona Hospital, Italy*)

Emilio Carbone (*University of Turin, Italy*)

Brunetto Chiarelli (*University of Florence, Italy*)

Amelia De Lucia (*University of Bari, Italy*)

Andrea Drusini (*University of Padua, Italy*)

Luciano Fadiga (*University of Ferrara, Italy*)

Vittorio Farina (*University of Sassari, Italy*)

William Galanter (*University of Illinois, USA*)

Millie Hughes-Fulford (*University of San Francisco, USA*)

Gaetano Leto (*University of Palermo, Italy*)

Gianni Losano (*University of Turin, Italy*)

Mansoor A. Malik (*Howard University Hospital, USA*)

Gian Luigi Mariottini (*University of Genoa, Italy*)

Neville A. Marsh (*Queensland University of Technology, Australia*)

Bruno Masala (*University of Sassari, Italy*)

Alejandro M.S. Mayer (*Midwestern University, USA*)

Vincenzo Mitolo (*University of Bari, Italy*)

Werner E.G. Muller (*Johannes Gutenberg University, Germany*)

Kary B. Mullis (*Oakland Research Institute, USA*)

Giuseppe Murdaca (*University of Genoa, Italy*)

Giuseppe Palumbo (*University of Naples Federico II, Italy*)

Gian Luigi Panattoni (*University of Turin, Italy*)

Giovanni Pizzuti (*University of Naples Federico II, Italy*)

Massimo Pregnolato (*University of Pavia, Italy*)

Mark R. Rasenick (*University of Illinois, USA*)

Angela Maria Rizzo (*University of Milan, Italy*)

Giacomo Rizzolatti (*University of Parma, Italy*)

Aldo Rustioni (*University of North Carolina, USA*)

Salvatore Sapienza (*University of Catania, Italy*)

Pietro Scotto Di Vettimo (*University of Naples, Italy*)

Vinicio Serino (*University of Siena, Italy*)

Lynne Christine Weaver (*University of Western Ontario, Canada*)

Mario Wiesendanger (*University of Friburg, Germany*)

Editorial Staff

Lucia Zoppi, Managing Editor

Claudia Castellano, Production Editor

Tiziano Taccini, Technical Support

Publisher

PAGEPress Publications

via Giuseppe Belli 7

27100 Pavia, Italy

Tel. +39.0382.1751762 – Fax. +39.0382.1750481

info@pagepress.org – www.pagepress.org

In vivo assay for the identification of potential inhibitors of epithelial-mesenchymal transition

R. La Tona,¹ A. Lavanco,² L. Anello,² A. Bongiovanni,² D.P. Romancino,² M. Di Bernardo²

¹Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, Palermo;

²Institute of Biomedicine and Molecular Immunology, National Research Center, Palermo, Italy

We designed and developed a simple and reproducible screening assay to explore the ability of a number of small compounds, interfering with evolutionary conserved signalling pathways, to inhibit epithelial mesenchymal transition (EMT) *in vivo*. EMT is an important process during development by which fully polarized epithelial cells acquire mesenchymal, fibroblast-like properties and show reduced intercellular adhesion and increased motility. EMT mechanism is re-activated in tumor progression, tissue invasion, metastasis and the acquisition of resistance to therapy.^{1,2} Targeting EMT, therefore, represents an important strategy for cancer treatment.

Sea urchin embryos provide a useful system to study EMT progression, just few hours after fertilization. The process is well characterized. Prior to ingression, the future primary mesenchyme cells (PMC) are indistinguishable from the neighbouring epithelial blastomeres, but their regulatory apparatus is actively preparing new molecular programs by which cells are going to turn on the expression of mesenchyme-specific molecular markers. Thus, at the right time PMCs, previously adherent to the adjacent epithelial cells via cadherin and adherens junctions, loose cell adhesion, enter the basal lamina and move through the blastocoele. Later, after migration to the proper *loci*, the specified PMCs will give rise to the embryonic skeleton.³

So far, potential EMT inhibitor compounds have been identified using a carcinoma cell line specifically induced to undergo EMT by the activation of growth factor signalling pathways.⁴ Nevertheless, this approach restricts the research to bio-molecules only affecting the selected growth factor induced signals and in some cases the reporter cell lines are not responsive to all exogenous growth factors known to be EMT inducers.

Here, we propose an *in vivo* screening assay, using sea urchin

embryos (Figure 1); we picked out a selection of pharmacologically active compounds from a commercial library (LOPAC¹²⁸⁰™, Sigma-Aldrich) and tested their ability to inhibit EMT in embryos. These molecules are known to interfere with some evolutionarily conserved signalling pathways: P38 mitogen-activated protein kinase (MAPK), platelet-derived growth factor receptors (PDGF-R) epidermal growth

factor receptor (EGFR) tyrosine-protein kinase (Src), Glycogen synthase kinase 3 (GSK-3). We set up the experiments as follows: two different batches of *Paracentrotus lividus* embryos at zygote (just post-fertilization) or hatching blastula (12h post-fertilization and 4h prior PMC ingression) stages were incubated in multiwell plates in the presence of different concentrations of the selected drug. Treated or control embryos were then monitored under an inverted microscope and scored for timely precise PMC formation, number and migration capability. Embryos were then photographed, phenotypically classified and in some experiments assayed for the expression of specific antigens. We obtained evidence that some of these compounds inhibit EMT and prevent the expression of mesenchymal specific molecular markers. We propose this low-, medium-throughput Sea Urchin embryonic EMT Assay (SU-EMTA) as an affordable and useful method to screen a high number of compounds, with potential anti-metastatic activity.

Correspondence: Daniele Romancino, Institute of Biomedicine and Molecular Immunology, National Research Center, via Ugo La Malfa 153, 90146 Palermo, Italy.

E-mail: daniele.romancino@ibim.cnr.it

Funding: the present study has been partially supported by a grant from the Italian Ministry of Economy and Finance to the CNR for the Project *FaReBio di Qualità*.

©Copyright R. La Tona et al., 2015

Licensee PAGEPress, Italy

Journal of Biological Research 2015; 88:5161

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 3.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.




Figure 1. A) Set up of a standard epithelial mesenchymal transition assay on sea urchin embryos; B) drug addition at fertilization (zygote) for 16 h or at hatching blastula stage (HB) for 4 h. Phenotype analysis at mesenchyme blastula stage (MB) and later (36 h after fertilization).

References

1. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. *J Clin Invest* 2009;119:1420-8.
2. Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. *Development* 2012;139:3471-86.
3. Wu S-Y, Ferkowicz M, McClay DR. Ingression of primary mesenchyme cells of the sea urchin embryo: a precisely timed epithelial mesenchymal transition. *Birth Defects Research* 2007; 81:241-52.
4. Chua KN, Sim W-J, Racine V, et al. A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma. *PLoS ONE* 2012;7:e33183.

Non commercial use only